Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 16/20 | 0.72 |
| ▸ | RET | P07949 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25359172 | 0.90 | ADORA1 (0.58) | ADORA1RETSLC6A3ADORA3ADORA2A | |
| SCHEMBL8031838 | 0.90 | ADORA1 (0.61) | ADORA1RETSLC6A3ADORA3ADORA2A | |
| SCHEMBL26010414 | 0.89 | ADORA1 (0.66) | ADORA1SLC6A3ADORA3ADORA2AADORA2B | |
| SCHEMBL26010416 | 0.87 | ADORA1 (0.66) | ADORA1SLC6A3ADORA3ADORA2AADORA2B | |
| SCHEMBL13913748 | 0.86 | ADORA1 (0.74) | ADORA1RETADORA3ADORA2AADORA2B | |
| SCHEMBL13914654 | 0.85 | RET (0.70) | ADORA1RETADORA3ADORA2AADORA2B | |
| SCHEMBL12553253 | 0.85 | ADORA1 (0.62) | ADORA1RETSLC6A3ADORA3ADORA2A | |
| SCHEMBL8034134 | 0.84 | ADORA1 (0.63) | ADORA1SLC6A3ADORA3ADORA2AADORA2B | |
| SCHEMBL26010418 | 0.84 | ADORA1 (0.79) | ADORA1SLC6A3ADORA2BKDM4EALDH1A1 | |
| SCHEMBL13913745 | 0.84 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170112-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | LUCY THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2025101598-A1 | BI-CYCLIC PYRIMIDINE COMPOUNDS, METHODS AND USES THEREOF | ZENO MANAGEMENT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025038783-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS OR CHRONIC HEART FAILURE | LUCY THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4479399-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Lucy Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023158725-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | LUCY THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158725-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | LUCY THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170112-A1 | ADENOSINE LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ADORA2A, ADORA1, PDE7A | ADORA1 2/4885RET 136/4885SLC6A3 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.